GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE

RAJYA SABHA
UNSTARRED QUESTION NO.251
TO BE ANSWERED ON 20TH JULY, 2021

MONTHLY MANUFACTURING CAPACITY OF COVID VACCINE MAKERS

251 SHRI MALLIKARJUN KHARGE:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

(a) the average monthly capacity of production of each manufacturer of COVID vaccine in the country, including Serum Institute and Bharat Biotech;

(b) the break-up of vaccines manufactured in 2021 by each manufacturer, month-wise;

(c) the average import quantity of vaccines from foreign companies;

(d) the procurement of said vaccines by Government or private sector from each manufacturer, month-wise;

(e) the vaccine production capacity planned to be increased in the coming months; and

(f) the plan of action to be taken in case the manufacturers fail to make the promised volume of vaccines?

ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE
(DR. BHARATI PRAVIN PAWAR)

(a) & (b): The current average monthly capacity of production of Covishield by M/s Serum Institute of India is 11 crore doses and of Covaxin by M/s Bharat Biotech International Limited is 2.5 crore doses.

From January 2021 to 16th July 2021 36.01 crore doses of Covishield have been supplied by M/s Serum Institute of India and 5.45 crore doses of Covaxin have been supplied by M/s Bharat Biotech International Limited for the National Covid Vaccination Programme.

(c): During 2021 (till 14th July 2021), a total of 3.3 million doses of Sputnik V (3 million 1st Component and 0.3 million 2nd component) have been imported.

(d): The procurement of COVID-19 vaccines by Government of India, State Government and Private Hospitals is 36.01 crore in respect of Covishield and 5.45 crore in respect of Covaxin from Jan 2021 to 16th Jul 2021.

(e): As communicated by manufacturers, the monthly vaccine production capacity of Covishield is planned to be increased from 11 crore doses per month to morethan 12 crore doses per month and production capacity of Covaxin is planned to be increase from 2.5 crore doses per month to 5.8 crore doses per month.

(f): The procurement process of COVID-19 vaccines has adequate in-built mechanisms of financial penalty in case of delay in delivery of vaccines by the manufacturers.